Organon (OGN) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
Organon (OGN) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Gsk |
93,162,528.78 Bn |
93,162,523.82 Bn |
7.76 Bn |
8.94% |
| 2 |
Eli Lilly |
1,017.87 Bn |
1,012.58 Bn |
16.22 Bn |
76.51% |
| 3 |
Johnson & Johnson |
575.51 Bn |
553.46 Bn |
15.96 Bn |
131.31% |
| 4 |
AbbVie |
400.43 Bn |
391.08 Bn |
10.78 Bn |
109.43% |
| 5 |
Merck |
294.19 Bn |
288.54 Bn |
12.09 Bn |
-51.68% |
| 6 |
Amgen |
182.41 Bn |
170.37 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
150.97 Bn |
143.24 Bn |
5.52 Bn |
27.11% |
| 8 |
Pfizer |
145.75 Bn |
132.97 Bn |
-1.21 Bn |
-146.62% |
| 9 |
Bristol Myers Squibb |
113.35 Bn |
102.90 Bn |
8.07 Bn |
5.72% |
| 10 |
Organon |
3.48 Bn |
2.37 Bn |
783.00 Mn |
-6.22% |
| Date | Value |
|---|
| Mar 31, 2026 |
-6.22% |
| Jun 30, 2024 |
270.24% |
| Mar 31, 2024 |
269.02% |
| Dec 31, 2023 |
312.62% |
| Sep 30, 2023 |
86.26% |
| Jun 30, 2023 |
95.74% |
| Mar 31, 2023 |
97.55% |
